LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) announces that a class action lawsuit has been filed on behalf of investors who purchased Roche Holding AG (“Roche” or the “Company”) (OTC: RHHBY) securities between March 2, 2017 through June 5, 2017 both dates inclusive (the “Class Period”). Roche investors have until August 7, 2017 to file a lead plaintiff motion. To obtain information or participate directly in this class action, please visit the Roche new case page on our website at www.glancylaw.com/case/roche-holding-ag.
Investors suffering losses on their Roche investments are encouraged to contact Lesley Portnoy of GPM to discuss their legal rights in this class action at 310-201-9150 or by email to email@example.com.
On June 5, 2017, news reports stated that a new study showed that adding Roche’s breast cancer drug Perjeta to its older treatment Herceptin only had a slight benefit, while more than doubling the one-year treatment cost; and that the combination of Perjeta with Herceptin had higher rates of certain side effects than Herceptin alone, including severe diarrhea. Following this news, Roche’s stock price dropped, which caused investors harm.
The complaint filed in this lawsuit alleges that throughout the Class Period, Defendants made materially false and misleading statements and/or failed to disclose issues with Roche’s breast cancer drugs Perjeta and Herceptin.
If you purchased shares of Roche during the Class Period you may move the Court no later than August 7, 2017 to ask the Court to appoint you as lead plaintiff if you meet certain legal requirements. To be a member of the Class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to firstname.lastname@example.org, or visit our website at http://glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.